Streetbeat News

Analyst Ratings

REPL

HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on Replimune Group (NASDAQ:REPL) and maintained a $51 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:14 am

COGT

HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Cogent Biosciences (NASDAQ:COGT) but lowers the price target from $28 to $27.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:13 am

VERA

HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Vera Therapeutics (NASDAQ:VERA) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:12 am

STOK

HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Stoke Therapeutics (NASDAQ:STOK) and maintained a $35 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:11 am

FHTX

HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Foghorn Therapeutics (NASDAQ:FHTX) and maintained a $20 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:09 am

HCP

Needham analyst Alex Henderson maintains a Buy rating on HashiCorp (NASDAQ:HCP) but lowers the price target from $39 to $34.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:08 am

TD

Credit Suisse analyst Amanda Abraham upgrades Toronto-Dominion Bank (TSX:TD) from Neutral to Outperform and raises the price target from C$85 to C$88.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:04 am

MMC

Evercore ISI Group analyst David Motemaden has upgraded Marsh & McLennan (NYSE:MMC) from In-Line to Outperform and raised the price target from $195 to $199.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:02 am

BIIB

Needham analyst Ami Fadia reiterates a Buy rating on Biogen (NASDAQ:BIIB) and maintains a $321 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 9:49 am

VRNT

Needham analyst Ryan MacDonald has reiterated a Buy rating on Verint Systems (NASDAQ:VRNT) and maintained a $50 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 9:49 am